본문 바로가기
KERD
논문KCI 등재

Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies

Qu Jun|Meng Fantao|Wang Zhen|Xu Wenhao
한국미생물·생명공학회 (The Korean Society For Microbiology And Biotechnology)|2024.12|Journal of Microbiology and Biotechnology|제34권 제12호|pp. 2413-2424|DOI 10.4014/jmb.2405.05019

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

atherosclerosisprobioticsprebioticssynbioticsMicrobiome dysbiosisTMAO inhibitors
주제분류생물학

초록

The microbial community inhabiting the human gut resembles a bustling metropolis, wherein beneficial bacteria play pivotal roles in regulating our bodily functions. These microorganisms adeptly break down resilient dietary fibers to fuel our energy, synthesize essential vitamins crucial for our well-being, and maintain the delicate balance of our immune system. Recent research indicates a potential correlation between alterations in the composition and activities of these gut microbes and the development of coronary artery disease (CAD). Consequently, scientists are delving into the intriguing realm of manipulating these gut inhabitants to potentially mitigate disease risks. Various promising strategies have emerged in this endeavor. Studies have evidenced that probiotics can mitigate inflammation and enhance the endothelial health of our blood vessels. Notably, strains such as Lactobacilli and Bifidobacteria have garnered substantial attention in both laboratory settings and clinical trials. Conversely, prebiotics exhibit anti-inflammatory properties and hold potential in managing conditions like hypertension and hypercholesterolemia. Synbiotics, which synergistically combine probiotics and prebiotics, show promise in regulating glucose metabolism and abnormal lipid profiles. However, uncertainties persist regarding postbiotics, while antibiotics are deemed unsuitable due to their potential adverse effects. On the other hand, TMAO blockers, such as 3,3-dimethyl-1-butanol, demonstrate encouraging outcomes in laboratory experiments owing to their anti-inflammatory and tissue-protective properties. Moreover, fecal transplantation, despite yielding mixed results, warrants further exploration and refinement. In this comprehensive review, we delve into the intricate interplay between the gut microbiota and CAD, shedding light on the multifaceted approaches researchers are employing to leverage this understanding for therapeutic advancements.

Abstract

The microbial community inhabiting the human gut resembles a bustling metropolis, wherein beneficial bacteria play pivotal roles in regulating our bodily functions. These microorganisms adeptly break down resilient dietary fibers to fuel our energy, synthesize essential vitamins crucial for our well-being, and maintain the delicate balance of our immune system. Recent research indicates a potential correlation between alterations in the composition and activities of these gut microbes and the development of coronary artery disease (CAD). Consequently, scientists are delving into the intriguing realm of manipulating these gut inhabitants to potentially mitigate disease risks. Various promising strategies have emerged in this endeavor. Studies have evidenced that probiotics can mitigate inflammation and enhance the endothelial health of our blood vessels. Notably, strains such as Lactobacilli and Bifidobacteria have garnered substantial attention in both laboratory settings and clinical trials. Conversely, prebiotics exhibit anti-inflammatory properties and hold potential in managing conditions like hypertension and hypercholesterolemia. Synbiotics, which synergistically combine probiotics and prebiotics, show promise in regulating glucose metabolism and abnormal lipid profiles. However, uncertainties persist regarding postbiotics, while antibiotics are deemed unsuitable due to their potential adverse effects. On the other hand, TMAO blockers, such as 3,3-dimethyl-1-butanol, demonstrate encouraging outcomes in laboratory experiments owing to their anti-inflammatory and tissue-protective properties. Moreover, fecal transplantation, despite yielding mixed results, warrants further exploration and refinement. In this comprehensive review, we delve into the intricate interplay between the gut microbiota and CAD, shedding light on the multifaceted approaches researchers are employing to leverage this understanding for therapeutic advancements.

참고문헌 (139)

  1. Thursby E, "Introduction to the human gut microbiota", Biochem. J, 474, pp.1823~1836 (2017)
  2. Eckburg PB, "Diversity of the human intestinal microbial flora", Science, 308, pp.1635~1638 (2005)
  3. Koenig JE, "Succession of microbial consortia in the developing infant gut microbiome", Proc. Natl. Acad. Sci. USA, 108(Suppl 1), pp.4578~4585 (2011)
  4. Faith JJ, "The long-term stability of the human gut microbiota", Science, 341, pp.1237439~ (2013)
  5. Guarner F, "Gut flora in health and disease", Lancet, 361, pp.512~519 (2003)
  6. Clemente JC, "The impact of the gut microbiota on human health : an integrative view", Cell, 148, pp.1258~1270 (2012)
  7. David LA, "Diet rapidly and reproducibly alters the human gut microbiome", Nature, 505, pp.559~563 (2014)
  8. Yatsunenko T, "Human gut microbiome viewed across age and geography", Nature, 486, pp.222~227 (2012)
  9. Turnbaugh PJ, "The effect of diet on the human gut microbiome : a metagenomic analysis in humanized gnotobiotic mice", Science Transl. Med, 1, pp.6ra14~6ra14 (2009)
  10. Pham VT, "Vitamins, the gut microbiome and gastrointestinal health in humans", Nutr. Res, 95, pp.35~53 (2021)
  11. Kang WK, "Vitamin B12 produced by gut bacteria modulates cholinergic signalling", Nat. Cell Biol, 26, pp.72~85 (2024)
  12. Cheng J, "Gut microbiota-derived short-chain fatty acids and depression : deep insight into biological mechanisms and potential applications", Gen. Psychiatr, 37, pp.e101374~ (2024)
  13. Wu M, "Gut complement induced by the microbiota combats pathogens and spares commensals", Cell, 187, pp.897~913 (2024)
  14. Garcia-Mantrana I, "Shifts on gut microbiota associated to mediterranean diet adherence and specific dietary intakes on general adult population", Front. Microbiol, 9, pp.319919~ (2018)
  15. Salvi PS, "Butyrate and the intestinal epithelium : modulation of proliferation and inflammation in homeostasis and disease", Cells, 10, pp.1775~ (2021)
  16. Barber TM, "The effects of the mediterranean diet on health and Gut Microbiota", Nutrients, 15, pp.2150~ (2023)
  17. Jardou M, "Solid organ transplantation and gut microbiota : a review of the potential immunomodulatory properties of short-chain fatty acids in graft maintenance", Front. Cell Infect. Microbiol, 14, pp.1342354~ (2024)
  18. Tang Y, "Potential therapeutic effects of short-chain fatty acids on chronic pain", Curr. Neuropharmacol, 22, pp.191~203 (2024)
  19. Zheng J, "Effects of short-chain fatty acids on blood glucose and lipid levels in mouse models of diabetes mellitus : a systematic review and network meta-analysis", Pharmacol. Res, 199, pp.107041~ (2024)
  20. Paraschiv AC, "Dysbiosis in multiple sclerosis : can immunoglobulin Y supplements help?", J. Gastrointestin. Liver Dis, 33, pp.115~122 (2024)
  21. Li O, "Roles of human gut microbiota in liver cirrhosis risk : a two-sample mendelian randomization study", J. Nutr, 154, pp.143~151 (2024)
  22. Virili C, "The relationship between thyroid and humanassociated microbiota : a systematic review of reviews", Rev. Endocr. Metab Disord, 25, pp.215~237 (2024)
  23. Ottinger S, "The human vaginal microbiota : from clinical medicine to models to mechanisms", Curr. Opin. Microbiol, 77, pp.102422~ (2024)
  24. Danne C, "Neutrophils : from IBD to the gut microbiota", Nat. Rev. Gastroenterol. Hepatol, 21, pp.184~197 (2024)
  25. Liu L, "The role of gut microbiota and associated compounds in cardiovascular health and its therapeutic implications", Cardiovasc. Hematol. Agents Med. Chem (2024)[DOI]
  26. Hamjane N, "Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review", Microvasc. Res, 151, pp.104601~ (2024)
  27. Hizo-Abes P, "Cardiovascular disease after Escherichia coli O157 : H7 gastroenteritis", CMAJ, 185, pp.E70~E77 (2013)
  28. Smeeth L, "Risk of myocardial infarction and stroke after acute infection or vaccination", New Engl. J. Med, 351, pp.2611~2618 (2004)
  29. Ziganshina EE, "Bacterial communities associated with atherosclerotic plaques from Russian individuals with atherosclerosis", PLoS One, 11, pp.e0164836~ (2016)
  30. Jonsson AL, "Role of gut microbiota in atherosclerosis", Nat. Rev. Cardiol, 14, pp.79~87 (2017)
  31. Lambert G, "The farnesoid X-receptor is an essential regulator of cholesterol homeostasis", J. Biol. Chem, 278, pp.2563~2570 (2003)
  32. Mori H, "Farnesoid X receptor, bile acid metabolism, and gut microbiota", Metabolites, 12, pp.647~ (2022)
  33. Wiedermann CJ, "Association of endotoxemia with carotid atherosclerosis and cardiovascular disease : prospective results from the bruneck study", J. Am. College Cardiol, 34, pp.1975~1981 (1999)
  34. Stoll LL, "Potential role of endotoxin as a proinflammatory mediator of atherosclerosis", Arterioscler. Thromb. Vasc. Biol, 24, pp.2227~2236 (2004)
  35. van den Munckhof IC, "Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease : a systematic review of human studies", Obes. Rev, 19, pp.1719~1734 (2018)
  36. Huang J, "Integrated miRNA and mRNA analysis identified potential mechanisms and targets of qianggan extracts in preventing nonalcoholic steatohepatitis", World J. Tradit. Chinese Med, 8, pp.77~ (2022)
  37. Wang X, "Effects of ferulic acid on regulating the neurovascular unit : implications for ischemic stroke treatment", World J. Tradit. Chin. Med, 8, pp.210~217 (2022)
  38. Dural AŞ, "Investigation of the relationship between serum low-density lipoprotein cholesterol levels with genetic polymorphisms, gut microbiota, and nutrition", Metab. Syndr. Relat. Disord, 22, pp.133~140 (2023)
  39. Hasan AU, "Interactions between host PPARs and gut microbiota in health and disease", Int. J. Mol. Sci, 20, pp.387~ (2019)
  40. Byndloss MX, "Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion", Science, 357, pp.570~575 (2017)
  41. Montaigne D, "PPAR control of metabolism and cardiovascular functions", Nat. Rev. Cardiol, 18, pp.809~823 (2021)
  42. Xia YM, "Characteristics of traditional Chinese medicine syndrome in patients with coronary heart disease at different disease stages", World J. Tradit. Chin Med, 8 (2022)[DOI]
  43. Tomas J, "High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine", Proc. Natl. Acad. Sci. USA, 113, pp.E5934~E5943 (2016)
  44. Natividad JM, "Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome", Cell Metab, 28, pp.737~749 (2018)
  45. Peng L, "The mechanism of Panax notoginseng in the treatment of heart failure based on biological analysis", World J. Tradit. Chin. Med, 8, pp.530~538 (2022)
  46. Wang Z, "Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease", Nature, 472, pp.57~63 (2011)
  47. Li XY, "Gut microbiota metabolite TMA may mediate the effects of TMAO on glucose and lipid metabolism in C57BL", 6J mice, 2024, pp.68, e2300443~
  48. Theofilis P, "Trimethylamine N-oxide levels in non-alcoholic fatty liver disease : a systematic review and meta-analysis", Metabolites, 12, pp.1243~ (2022)
  49. Toh JZK, "A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease", Clin. Gastroenterol. Hepatol, 20, pp.2462~2473 (2022)
  50. Wan SY, "Recent advances of traditional Chinese medicine in the regulation of myocardial mitochondrial function", World J. Tradit. Chinese Med, 8, pp.50~58 (2022)
  51. Rath S, "Uncovering the trimethylamine-producing bacteria of the human gut microbiota", Microbiome, 5, pp.54~ (2017)
  52. Romano K, "FE Rey Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide", pp.e02481~ (2015)[DOI]
  53. Rath S, "Potential TMA-producing bacteria are ubiquitously found in mammalia", Front. Microbiol, 10, pp.500963~ (2020)
  54. Tang WW, "Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk", New Engl. J. Med, 368, pp.1575~1584 (2013)
  55. Heianza Y, "Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death : a systematic review and meta-analysis of prospective studies", J. Am. Heart Assoc, 6, pp.e004947~ (2017)
  56. Schiattarella GG, "Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker : a systematic review and dose-response meta-analysis", Eur. Heart J, 38, pp.2948~2956 (2017)
  57. Huang YX, "Network pharmacology-based dissection of the bioactive compounds and pharmacological mechanisms of yiqi fumai lyophilized injection for the treatment of heart failure", World J. Tradit. Chin. Med, 10, pp.75~82 (2024)
  58. Fan Y, "Gut microbiota in human metabolic health and disease", Nat. Rev. Microbiol, 19, pp.55~71 (2021)
  59. Jia J, "Assessment of causal direction between gut microbiota–dependent metabolites and cardiometabolic health : a bidirectional Mendelian randomization analysis", Diabetes, 68, pp.1747~1755 (2019)
  60. Wang CH, "Dalbergia odorifera essential oil protects against myocardial ischemia through upregulating nrf2 and inhibiting caspase signaling pathways in isoproterenol-induced rats", World J. Tradit. Chin. Med, 9, pp.338~347 (2023)
  61. Tousoulis D, "Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases : a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation", Cardiovasc. Res, 118, pp.3171~3182 (2022)
  62. Hu YR, "Jujuboside a improved energy metabolism in senescent H9c2 cells injured by ischemia, hypoxia, and reperfusion through the CD38", silent mating type information regulation 2 homolog 3 signaling pathway, 2023, pp.9, 322~329
  63. Jie Z, "The gut microbiome in atherosclerotic cardiovascular disease", Nat. Commun, 8, pp.845~ (2017)
  64. Yin J, "Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack", J. Am. Heart Assoc, 4, pp.e002699~ (2015)
  65. Zhu Q, "Dysbiosis signatures of gut microbiota in coronary artery disease", Physiol. Genomics, 50, pp.893~903 (2018)
  66. Gibson GR, "Expert consensus document : the International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of prebiotics", Nat. Rev. Gastroenterol. Hepatol, 14, pp.491~502 (2017)
  67. Wu H, "Potential benefits of probiotics and prebiotics for coronary heart disease and stroke", Nutrients, 13, pp.2878~ (2021)
  68. Parnell JA, "Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults2", Am. J. Clin. Nutr, 89, pp.1751~1759 (2009)
  69. Monteagudo-Mera A, "Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health", Appl. Microbiol. Biotechnol, 103, pp.6463~6472 (2019)
  70. Kendrick SFW, "Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis", Hepatology, 51, pp.1988~1997 (2010)
  71. Usami M, "Butyrate and trichostatin A attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells", Nutr. Res, 28, pp.321~328 (2008)
  72. Pang XB, "Study on the effect of ginaton on reducing cerebral vasospasm and early brain injury after hemorrhagic stroke by inhibiting inflammatory response", World J. Tradit. Chin. Med, 10, pp.33~39 (2024)
  73. Zhang SD, "Exploring the pathways and targets of shexiang baoxin pill for coronary heart disease through a network pharmacology approach", World J. Tradit. Chin. Med, 4, pp.137~146 (2018)
  74. Liu X, "Effect of herb-partitioned moxibustion on structure and functional prediction of gut microbiota in rats with irritable bowel syndrome with diarrhea", World J. Tradit. Chin. Med, 9, pp.141~149 (2023)
  75. Cheng D, "Butyrate ameliorated-NLRC3 protects the intestinal barrier in a GPR43-dependent manner", Exper. Cell Res, 368, pp.101~110 (2018)
  76. EFSA Panel on Dietetic Products N, Allergies, "Scientific opinion on the substantiation of health claims related to various food(s)", food constituents(s)and increasing numbers of gastro-intestinal microorganisms(ID 760, 761, 779, 780, 779, 1905), and decreasing potentially pathogenic gastro-intestinal microorganisms(ID 760, 761, 779, 780, 779, 1905)pursuant to Article 13(1)of Regulation(EC)No 1924, EFSA J, pp.2010 (2006), 8[DOI]
  77. Wouk J, "β-Glucans as a panacea for a healthy heart? Their roles in preventing and treating cardiovascular diseases", Int. J. Biol. Macromol, 177, pp.176~203 (2021)
  78. Sun Y, "Effects of dachaihu decoction and Its"Prescription Elements"on intestinal flora of nonalcoholic fatty liver disease model rats", World J. Tradit. Chin. Med, 6, pp.97~105 (2020)
  79. Aarsæther E, "Cardioprotective effect of pretreatment with β-glucan in coronary artery bypass grafting", Scand. Cardiovasc. J, 40, pp.298~304 (2006)
  80. Dehghan P, "Impact of prebiotic supplementation on T-cell subsets and their related cytokines, anthropometric features and blood pressure in patients with type 2 diabetes mellitus : a randomized placebo-controlled Trial", Complement. Ther. Med, 24, pp.96~102 (2016)
  81. Merino-Aguilar H, "Effect of fructooligosaccharides fraction from Psacalium decompositum on inflammation and dyslipidemia in rats with fructose-induced obesity", Nutrients, 6, pp.591~604 (2014)
  82. Jiang T, "Chitosan oligosaccharides show protective effects in coronary heart disease by improving antioxidant capacity via the increase in intestinal probiotics", Oxid. Med. Cell. Longev, 2019, pp.7658052~ (2019)
  83. Santos-Marcos JA, "The role of diet and intestinal microbiota in the development of metabolic syndrome", J. Nutr. Biochem, 70, pp.1~27 (2019)
  84. Healey G, "Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic : a randomised, double-blind, placebo-controlled, cross-over, human intervention study", Br. J. Nutr, 119, pp.176~189 (2018)
  85. Canfora EE, "Supplementation of diet with galactooligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals", Gastroenterology, 153, pp.87~97 (2017)
  86. Ramnani P, "A randomised, double-blind, cross-over study investigating the prebiotic effect of agave fructans in healthy human subjects", J. Nutr. Sci, 4, pp.e10~ (2015)
  87. Ohashi Y, "Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine", Benef Microbes, 6, pp.451~455 (2015)
  88. Mahdavi-Roshan M, "The effects of probiotics on inflammation, endothelial dysfunction, and atherosclerosis progression : a mechanistic overview", Heart Lung Circ, 31, pp.e45~e71 (2022)
  89. Hill C, "The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic", Nat. Rev. Gastroenterol. Hepatol, 11, pp.506~514 (2014)
  90. O'Morain VL, "The potential of probiotics in the prevention and treatment of atherosclerosis", Mol. Nutr. Food Res, 64, pp.1900797~ (2020)
  91. Moludi J, "Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients : a double blind placebo controlled randomized clinical trial", Nutr. J, 20, pp.47~ (2021)
  92. Malik M, "Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease", Circ. Res, 123, pp.1091~1102 (2018)
  93. Koppinger MP, "Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow", Am. J. Physiol. Heart Circ. Physiol, 319, pp.H32~H41 (2020)
  94. Sun B, "Bifidobacterium lactis Probio-M8 adjuvant treatment confers added benefits to patients with coronary artery disease via target modulation of the gut-heart", -brain axes, 2022, pp.7, e00100-22~
  95. Yoshida N, "Bacteroides vulgatus and bcteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis", Circulation, 138, pp.2486~2498 (2018)
  96. O'Morain VL, "The Lab4P consortium of probiotics attenuates atherosclerosis in LDL receptor deficient mice fed a high fat diet and causes plaque stabilization by inhibiting inflammation and several pro-atherogenic processes", Mol. Nutr. Food Res, 65, pp.2100214~ (2021)
  97. Gan XT, "Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat", Circ. Heart Fail, 7, pp.491~499 (2014)
  98. Aboulgheit A, "Lactobacillus plantarum probiotic induces Nrf2-mediated antioxidant signaling and eNOS expression resulting in improvement of myocardial diastolic function", Am. J. Physiol. Heart Circ. Physiol, 321, pp.H839~h849 (2021)
  99. Neverovskyi A, "Probiotic Lactobacillus plantarum may reduce cardiovascular risk : an experimental study", ARYA Atheroscler, 17, pp.1~10 (2021)
  100. Hofeld BC, "Lactobacillus plantarum 299v probiotic supplementation in men with stable coronary artery disease suppresses systemic inflammation", Sci. Rep, 11, pp.3972~ (2021)
  101. Tarrah A, "Lactobacillus paracasei DTA81, a cholesterol-lowering strain having immunomodulatory activity, reveals gut microbiota regulation capability in BALB", c mice receiving high-fat diet, 2021, pp.131, 1942~1957
  102. Sun J, "Effects of probiotics consumption on lowering lipids and CVD risk factors : a systematic review and metaanalysis of randomized controlled trials", Annal. Med, 47, pp.430~440 (2015)
  103. de Araújo Henriques Ferreira G, "Potentially probiotic Limosilactobacillus fermentum fruit-derived strains alleviate cardiometabolic disorders and gut microbiota impairment in male rats fed a high-fat diet", Probiotics Antimicrob. Proteins, 14, pp.349~359 (2022)
  104. de Luna Freire MO, "Limosilactobacillus fermentum strains with claimed probiotic properties exert anti-oxidant and anti-inflammatory properties and prevent cardiometabolic disorder in female rats fed a high-fat diet", Probiotics Antimicrob. Proteins, 15, pp.601~613 (2023)
  105. Zafar H, "Lacticaseibacillus rhamnosus FM9 and Limosilactobacillus fermentum Y57 Are as effective as statins at improving blood lipid profile in high cholesterol, high-fat diet model in male wistar rats", Nutrients, 14, pp.1654~ (2022)
  106. Romão da Silva LdF, "Effects of probiotic therapy on cardio-metabolic parameters and autonomic modulation in hypertensive women : a randomized, triple-blind, placebocontrolled trial", Food Funct, 11, pp.7152~7163 (2020)
  107. Sethi NJ, "Antibiotics for secondary prevention of coronary heart disease", Cochrane Database Syst. Rev, (7) (2017)
  108. Taylor-Robinson D, "The failure of antibiotics to prevent heart attacks", BMJ, 331, pp.361~362 (2005)
  109. Ott SJ, "Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease", Circulation, 113, pp.929~937 (2006)
  110. Gupta S, "Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction", Circulation, 96, pp.404~407 (1997)
  111. Cannon CP, "Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome", N. Engl. J. Med, 352, pp.1646~1654 (2005)
  112. Grayston JT, "Azithromycin for the secondary prevention of coronary events", N. Engl. J. Med, 352, pp.1637~1645 (2005)
  113. Salminen S, "The International Scientific Association of Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of postbiotics", Nat. Rev. Gastroenterol. Hepatol, 18, pp.649~667 (2021)
  114. Plovier H, "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice", Nat. Med, 23, pp.107~113 (2017)
  115. Swanson KS, "The International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of synbiotics", Nat. Rev. Gastroenterol. Hepatol, 17, pp.687~701 (2020)
  116. Sáez-Lara MJ, "Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease : a review of human clinical trials", Int. J. Mol. Sci, 17, pp.928~ (2016)
  117. Arabi SM, "Impact of synbiotic supplementation on cardiometabolic and anthropometric indices in patients with metabolic syndrome : a systematic review and meta-analysis of randomized controlled trials", Pharmacol. Res, 176, pp.106061~ (2022)
  118. Tajabadi-Ebrahimi M, "A Randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease", Exp. Clin. Endocrinol. Diabetes, 125, pp.21~27 (2016)
  119. Shakeri H, "Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes", Lipids, 49, pp.695~701 (2014)
  120. Moayyedi P, "Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea : a systematic review of randomised controlled trials", Med. J. Australia, 207, pp.166~172 (2017)
  121. Vrieze A, "Transfer of iIntestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome", Gastroenterology, 143, pp.913~916 (2012)
  122. Smits LP, "Effect of vegan fecal microbiota transplantation on carnitine-and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome", J. Am. Heart Assoc, 7, pp.e008342~ (2018)
  123. Hu XF, "Fecal microbiota transplantation alleviates myocardial damage in myocarditis by restoring the microbiota composition", Pharmacol. Res, 139, pp.412~421 (2019)
  124. Brandsma E, "A Proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis", Circ. Res, 124, pp.94~100 (2019)
  125. Kim ES, "Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q", TNF-related protein 9 genetic deficiency, 2022, pp.54, 103~114
  126. Wang Z, "Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis", Cell, 163, pp.1585~1595 (2015)
  127. Chen K, "Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice", Front. Physiol, 8, pp.139~ (2017)
  128. Zou D, "Attenuation of circulating trimethylamine N-oxide prevents the progression of cardiac and renal dysfunction in a rat model of chronic cardiorenal syndrome", Front. Pharmacol, 12, pp.751380~ (2021)
  129. Brunt VE, "Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans", Hypertension, 76, pp.101~112 (2020)
  130. Li T, "Elevated circulating trimethylamine N-oxide levels contribute to endothelial dysfunction in aged rats through vascular inflammation and oxidative stress", Front. Physiol, 8, pp.350~ (2017)
  131. Chen CY, "Inhibition of trimethylamine N-oxide attenuates neointimal formation through reduction of inflammasome and oxidative stress in a mouse model of carotid artery ligation", Antioxid. Redox Signal, 38, pp.215~233 (2022)
  132. Roberts AB, "Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential", Nat. Med, 24, pp.1407~1417 (2018)
  133. Organ CL, "Nonlethal inhibition of gut microbial trimethylamine N-oxide production improves cardiac function and remodeling in a murine model of heart failure", J. Am. Heart Assoc, 9, pp.e016223~ (2020)
  134. Pathak P, "Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism", Am. J. Physiol. Heart Circ. Physiol, 318, pp.H1474~h1486 (2020)
  135. Witkowski M, "Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis", Cardiovasc. Res, 118, pp.2367~2384 (2021)
  136. Zhou P, "Virtual screening analysis of natural flavonoids as trimethylamine(TMA)-lyase inhibitors for coronary heart disease", J. Food Biochem, 46, pp.e14376~ (2022)
  137. Micek A, "Dietary flavonoids and cardiovascular disease : a comprehensive doseresponse meta-analysis", Mol. Nutr. Food Res, 65, pp.e2001019~ (2021)
  138. Barrea L, "Trimethylamine N-oxide, mediterranean diet, and nutrition in healthy, normal-weight adults : also a matter of sex?", Nutrition, 62, pp.7~17 (2019)
  139. Pignanelli M, "Mediterranean diet score : associations with metabolic products of the intestinal microbiome, carotid plaque burden, and renal function", Nutrients, 10, pp.779~ (2018)

관련 논문AI추천

Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic DiseasesAnhê Fernando F., Jensen Benjamin A. H., Marette André, Perazza Lais Rossi, Schertzer Jonathan D., Tchernof André한국지질동맥경화학회 · 지질·동맥경화학회지2021 · 제10권 제2호Role of Probiotics in Human Gut Microbiome-Associated Diseases권준기, 김선균, 김유태, 김현범, 김혜리, 이주훈, 조재형, Robin B. Guevarra한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2019 · 제29권 제9호Gut microbiota-generated metabolites: missing puzzles to hosts’ health, diseases, and aging유동렬, 하기태, Hang Zhang, Hyun Joo Lee, Jongkil Joo, Jong-Sun Kang, Shibo Wei, Yan Zhang, Yunju Jo생화학분자생물학회 · BMB Reports2024 · 제57권 제5호Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency김상엽, 김태범, 백인정, 정진용, 정창희, Choi Min, Ha Chang Hoon, Kim Eun Hye, Kim Eun Sil, Lee Byong-Wook, Lee Seung Min, Pack Chan-Gi, Sung Young Hoon, Yoon Bo Hyun생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Personalized Diets based on the Gut Microbiome as a Target for Health Maintenance: from Current Evidence to Future PossibilitiesShin Ji-Hee, Song Eun-Ji한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2022 · 제32권 제12호The gut microbiota: a key regulator of metabolic diseases권미나, 양진영생화학분자생물학회 · BMB Reports2016 · 제49권 제10호

이 간행물의 다른 논문 (29건)

Innovative Bacterial Therapies and Genetic Engineering Approaches in Colorectal Cancer: A Review of Emerging Strategies and Clinical ImplicationsSong Chunxiao, Zhao Chunwupp. 2397-2412A Comprehensive Review of Naringenin, a Promising Phytochemical with Therapeutic PotentialShin Seung Ho, Shin Jun Hongpp. 2425-2438Shiga Toxins Produced by Enterohaemorrhagic Escherichia coli Induce Inflammation in Toxin-Sensitive Cells through the p38 MAPK/MK2/Tristetraprolin Signaling PathwayTesh Vernon L., Lee Kyung-Soo, Park Jun-Young, Jeong Yujin, Lee Moo-Seung, Park Jongsun, Park Seo Youngpp. 2439-2449Triple-Branch Catalytic Assembly DNAzyme Motivated DNA Tweezer for Sensitive and Reliable mecA Gene Detection in Staphylococcus aureusGan Fangmin, Li Xiaoyang, Xu Meiyan, Zhao Huipp. 2450-2456Inhibitory Effects of Cryptotanshinone and Dihydrotanshinone I on Intracellular Trafficking of Viral GlycoproteinsLee Dong-Sun, Muroi Makotopp. 2457-2464
원문 보기